

## PRESS PROGRAM SCHEDULE

### AIDS Vaccine 2013

*All press events will be held in Room 120 on level one of Barcelona's International Convention Center.  
Embargoes on research presented in AIDS Vaccine 2013 press conferences lift at the end of the press briefing or  
at the end of the conference session in which the study is presented, whichever is earlier.*

**Monday, 7 October, 10:30 – 11:30 a.m.**

---

#### Opening Press Conference

**Chair: Bill Snow**, Global HIV Vaccine Enterprise, USA

Introduction to AIDS Vaccine 2013

**Bonaventura Clotet**, Institute for AIDS Research IrsiCaixa, HIVACAT Program for HIV Vaccine Research, Spain

HIV Vaccine Research in Spain

**José Gatell**, Hospital Clínic-IDIBAPS, University of Barcelona, HIVACAT Program for HIV Vaccine Research, Spain

Community Participation in HIV Vaccine Research

**Laia Ruiz Mingote**, HIVACAT Community Advisory Board

Partnership Towards a Tough Target

**Ntando Yola**, NACOSA, South Africa

An HIV Vaccine for Global and Individual Viral Eradication

**Anthony Fauci**, National Institutes of Health, USA

Introduction to HIV Research for Prevention 2014 (HIVR4P)

**Eric Hunter**, Emory University, USA

*Media representatives, who cannot attend in person may participate by phone. Telephone access details may be found here, <http://vaccineenterprise.org/conference/2013/sites/default/files/Conf.%20Lines.pdf>. Questions may be submitted in advance to [jbrunet@vaccineenterprise.org](mailto:jbrunet@vaccineenterprise.org).*

All press events will be held in Room 120 on level one of Barcelona's International Convention Center. Embargoes on research presented in AIDS Vaccine 2013 press conferences lift at the end of the press briefing or at the end of the conference session in which the study is presented, whichever is earlier.

**Tuesday, 8 October, 12:00 p.m. – 1:00 p.m. (12h00 – 13h00)**

---

### **New Approaches to HIV Vaccine Design**

**Chair: Christian Brander**, Institute for AIDS Research IrsiCaixa, HIVACAT Program for HIV Vaccine Research

Pre-clinical Development of Cytomegalovirus Vectors (S03.03, Tues. 8 Oct., 15h40)  
**Louis Picker**, Oregon Health & Science University, USA

Protection of Cynomolgus Macaques from pathogenic SIV following vaccination with Varicella-Zoster virus based vaccines (OA04.05, Tues., 8 Oct., 14h00)  
**Kelly MacDonald**, University of Toronto, Canada

HIV-1 gp120 Vaccination Elicits a Robust and Durable Anti-V1/V2 IgG Response and yet no HIV-1 Env-specific IgA Response in HIV-exposed Infants (OA05.06, Tues. 8 Oct., 14h15)  
**Genevieve Fouda**, Duke University, USA

Genetic Selection Bias at the Heterosexual HIV-1 Transmission Bottleneck (OA07.06 LB, Wed., 9 Oct., 11h45)  
**Eric Hunter**, Emory University, USA

*Media representatives, who cannot attend in person may participate by phone. Telephone access details may be found here, <http://vaccineenterprise.org/conference/2013/sites/default/files/Conf.%20Lines.pdf>. Questions may be submitted in advance to [jbrunet@vaccineenterprise.org](mailto:jbrunet@vaccineenterprise.org).*

*All press events will be held in Room 120 on level one of Barcelona's International Convention Center.  
Embargoes on research presented in AIDS Vaccine 2013 press conferences lift at the end of the press briefing or  
at the end of the conference session in which the study is presented, whichever is earlier.*

**Wednesday, 9 October, 12:00 p.m. – 1:00 p.m. (12h00 – 13h00)**

---

### **New Insights from HIV Vaccine Clinical Trials**

**Chair: Scott Hammer**, Columbia University, USA

The HIVIS and TaMoVac Studies a North-South Collaboration (PL04.02, Thurs., 10 Oct., 10h55 – 11h20)

**Muhammad Bakari**, Muhimbili University of Health and Allied Sciences, Tanzania

Vaccine Induced Antibody Responses in HVTN 505, a Phase IIb HIV-1 Efficacy Trial (PL04.04, Thurs., 10 Oct., 11h45)

**Georgia Tomaras**, Duke University, USA

An Update on the Phambili/HVTN 503 Study, a Phase IIB HIV Vaccine Efficacy Study Investigating MRK Ad5 HIV-1 Subtype B gag/pol/nef Vaccine (PL04.05, Thurs., 10 Oct., 14h12 – 14h35)

**Glenda Gray**, Perinatal HIV Research Unit, South Africa

Meta-Analysis of Ad5-vector HIV Vaccine Trials to Assess the Vaccine Effect on HIV Acquisition (PL04.06, Thurs., 10 Oct., 12h35 – 14h00)

**Peter Gilbert**, Fred Hutchinson Cancer Research Center, USA

Looking Back to Move Forward: Understanding ALVAC/AIDS VAX Immune Responses (PL04.03, Thurs., 10 Oct., 11h20)

**Merlin Robb**, U.S. Military HIV Research Program